First European Commission approval of a bispecific antibody discovered using OmniAb OmniAb, Inc. is eligible to receive a $10 million milestone upon…
Transaction will result in OmniAb becoming an independent publicly traded company Ligand’s shareholders to receive 100% of Ligand’s shares in OmniAb through
Sugemalimab was discovered using the OmniAb platform EMERYVILLE, Calif.–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner CStone Pharmaceuticals (HKEX: 2616)
Strategic Decision Based Upon Recent Business Success and Plans to Support Continued Growth and Investments in OmniAb’s Drug Discovery Platform Conference Call
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company Read More »
First regulatory approval of an OmniAb-derived antibody EMERYVILLE, Calif.–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Gloria Biosciences (GloriaBio) has
NANJING, China and SAN DIEGO, June 2, 2021 /PRNewswire/ — GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated…
Two large pharma partners reach clinical-development milestones with OmniAb-derived antibody programs and Ligand earns $4.5 million in milestone payments…
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen…
SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb partner Immunovant, Inc. (NASDAQ: IMVT) announced positive topline results from…
CS1001 is the first anti-PD-L1 mAb to demonstrate overwhelming efficacy as First Line treatment of Stage IV squamous and non-squamous NSCLC in a randomized, double-blind Phase…
